[ parking, ignore ]
the oldest description of the OSIP/Pfizer deal that I've been able to find.......
In April 1986, Pfizer and the Company entered into a collaborative
research agreement and several other related agreements. During the first five
years of the collaboration, the Company and Pfizer focused principally on
understanding the molecular biology of oncogenes. In 1991, Pfizer and the
Company renewed the collaboration for a second five-year term and expanded the
resources and scope of the collaboration to focus on the discovery and
development of cancer therapeutic products based on mechanisms-of-action that
target oncogenes and anti-oncogenes. Oncogenes play a key role in the conversion
of normal cells to a cancerous state and can cause cancer when they mutate or
over express. Anti-oncogenes, or tumor suppressor genes, encode proteins that
generally function to block the proliferative growth of particular cell types. A
loss of function of certain tumor suppressor genes can result in uncontrolled
cell growth. Effective April 1, 1996, the Company and Pfizer renewed their
collaboration for a new five-year term by entering into new collaborative
research and license agreements.
Currently, the Company's collaboration with Pfizer focuses on
discovering compounds that act upon various target proteins involved in cancer.
The Company's screening program has resulted in the identification of a
proprietary lead compound, CP-358,774, that inhibits the activity of the
Epidermal Growth Factor Receptor, a protein associated with a number of major
cancers. Pfizer is conducting Phase I safety and toxicity studies in the United
States on this compound. The continued development of this compound depends on
several factors outside the control of the Company, including the amount and
timing of resources devoted by Pfizer, successful completion of safety and
toxicity studies and successful optimization of the compound. There can be no
assurance that a drug will result from this program.
All patent rights and patentable inventions derived from the research
under this collaboration are owned jointly by the Company and Pfizer. The
Company has granted Pfizer an exclusive, worldwide license to make, use, and
sell the therapeutic products resulting from this collaboration in exchange for
royalty payments. This license terminates on the date of the last to expire of
the Company's relevant patent rights.
|
